Daiichi Sankyo Co. Ltd.'s top-line announcement that its investigational, oral FLT-3 targeting quizartinib demonstrated an overall survival benefit in a Phase III acute myeloid leukemia (AML) study gives the company a leg up in oncology, but it remains to be seen whether the drug will be able to compete in this niche space.
AML is a small indication with 21,000 new diagnoses in the US in 2017, and about one-third of these cases...